Computational prediction of the cross‐reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV‐1 gp120
- 1 September 2006
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 20 (11) , 1762-1774
- https://doi.org/10.1096/fj.05-5509rev
Abstract
Backtracking from antibodies to their corresponding epitopes is a rational approach for vaccine design. Here we apply such a reverse immunological strategy for mapping the cross-reactive neutralizing epitope corresponding to the monoclonal antibody (mAb) b12 specific for HIV-1 gp120. b12 was used to screen a combinatorial phage display random peptide library and nineteen 12mer cysteine-looped peptides were affinity purified. These were used as input for analysis with the predictive algorithm Mapitope. Based on the input panel of peptides and the antigen’s atomic structure, Mapitope predicts candidate epitopes on the surface of the antigen. Two major clusters were predicted as candidate b12 epitopes. These could be discriminated by a series of experiments, which included point mutagenesis of selected residues and binding assays. Moreover, the prediction of the b12 epitope was further strengthened by comparison with additional predictions for two competing antibodies, b6 and m14. Finally, support of our prediction was obtained in view of the fact that b12, m14, and b6 were found to compete against mAb 17b binding to gp120. The b12 epitope is predicted to consist of four peptide segments of gp120 (residues V254-T257, D368-F376, E381-Y384, and I420-I424), which lie at the periphery of the CD4 binding site.—Bublil, E. M., Yeger-Azuz, S., Gershoni, J. M. Computational prediction of the cross-reactive neutralizing epitope corresponding to monoclonal antibody b12 specific for HIV-1 gp120.Keywords
This publication has 59 references indexed in Scilit:
- DNA Vaccines: Progress and ChallengesThe Journal of Immunology, 2005
- Measles Vaccines and the Potential for Worldwide Eradication of MeaslesPediatrics, 2004
- Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in ElderlyInfection, 2004
- Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity DataEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- The Mapping and Reconstitution of a Conformational Discontinuous B-cell Epitope of HIV-1Journal of Molecular Biology, 2003
- Vaccinology: past achievements, present roadblocks and future promisesVaccine, 2003
- Augmented Serum Neutralizing Activity against Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Isolates in Two Groups of HIV‐1‐Infected Long‐Term NonprogressorsThe Journal of Infectious Diseases, 1997
- Smallpox: The Triumph over the Most Terrible of the Ministers of DeathAnnals of Internal Medicine, 1997
- Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adultsVaccine, 1995
- Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal AntibodyScience, 1994